Israel Englander Millennium Management
Israel “Izzy” Englander is the founder of Millennium Management, one of the world’s largest multi-strategy hedge fund platforms. Millennium allocates capital across hundreds of independent teams rather than a single house view, with rigorous risk controls at the platform level. Englander’s model has been highly influential in the rise of pod-shop multi-manager structures across the industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$643M |
| 2 |
AT&T
T
|
+$311M |
| 3 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$306M |
| 4 |
Microsoft
MSFT
|
+$292M |
| 5 |
Ametek
AME
|
+$215M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$887M |
| 2 |
Apple
AAPL
|
+$694M |
| 3 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
+$616M |
| 4 |
Amazon
AMZN
|
+$596M |
| 5 |
Linde
LIN
|
+$531M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 58.05% |
| 2 | Technology | 7.69% |
| 3 | Financials | 6.83% |
| 4 | Healthcare | 6.42% |
| 5 | Industrials | 4.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3801
Denali Therapeutics
DNLI
$3.84B
| $2.11M | ﹤0.01% |
41,842
+22,399
| +115% | +$1.26M |
|
3802
CRA International
CRAI
$1.1B
| $2.11M | ﹤0.01% |
21,205
-893
| -4% | -$80.6K |
|
|
NBIS
3803
Nebius Group N.V.
NBIS
$56.9B
| $2.1M | ﹤0.01% |
+26,409
| New | +$1.92M |
|
3804
CALL
UiPath
PATH
$9.4B
| $2.1M | ﹤0.01% |
+40,000
| New | +$2.42M |
|
|
HCAR
3805
DELISTED
Healthcare Services Acquisition Corporation Class A Common Stock
HCAR
| $2.1M | ﹤0.01% |
215,794
+171,342
| +385% | +$1.66M |
|
3806
CarGurus
CARG
$3.26B
| $2.1M | ﹤0.01% |
66,969
-181,402
| -73% | -$5.29M |
|
3807
PUT
Vornado Realty Trust
VNO
$7.13B
| $2.09M | ﹤0.01% |
49,800
+20,000
| +67% | +$862K |
|
|
SLCA
3808
DELISTED
U.S. SILICA HOLDINGS, INC.
SLCA
| $2.09M | ﹤0.01% |
261,632
-45,278
| -15% | -$428K |
|
|
ZWRK
3809
DELISTED
Z-Work Acquisition Corp. Class A Common Stock
ZWRK
| $2.09M | ﹤0.01% |
214,573
-30,192
| -12% | -$292K |
|
3810
Cimpress
CMPR
$2.17B
| $2.09M | ﹤0.01% |
24,048
-2,901
| -11% | -$284K |
|
3811
Outlook Therapeutics
OTLK
$156M
| $2.08M | ﹤0.01% |
+48,013
| New | +$2.32M |
|
|
PFDRU
3812
DELISTED
Pathfinder Acquisition Corporation Unit
PFDRU
| $2.08M | ﹤0.01% |
208,000
-577,850
| -74% | -$5.79M |
|
3813
Annovis Bio
ANVS
$73.3M
| $2.08M | ﹤0.01% |
65,619
+62,032
| +1,729% | +$3.57M |
|
|
RAPT
3814
PUT
DELISTED
RAPT Therapeutics
RAPT
| $2.08M | ﹤0.01% |
+8,375
| New | +$2.21M |
|
3815
ACNB Corp
ACNB
$656M
| $2.08M | ﹤0.01% |
74,225
-46,922
| -39% | -$1.32M |
|
3816
Black Diamond Therapeutics
BDTX
$128M
| $2.08M | ﹤0.01% |
245,517
-82,641
| -25% | -$816K |
|
3817
Eagle Bancorp
EGBN
$840M
| $2.08M | ﹤0.01% |
36,080
+24,033
| +199% | +$1.35M |
|
|
MITT
3818
TPG Mortgage Investment Trust
MITT
$213M
| $2.08M | ﹤0.01% |
181,538
-123,846
| -41% | -$1.36M |
|
3819
Raymond James Financial
RJF
$34.5B
| $2.08M | ﹤0.01% |
22,488
-69,831
| -76% | -$6.26M |
|
3820
Franklin Templeton
BEN
$17.6B
| $2.07M | ﹤0.01% |
69,743
-273,148
| -80% | -$8.52M |
|
3821
Spectral AI
MDAI
$50.5M
| $2.07M | ﹤0.01% |
213,522
-138,902
| -39% | -$1.35M |
|
3822
Tecnoglass Holdings
TGLS
$1.78B
| $2.07M | ﹤0.01% |
+95,398
| New | +$2.01M |
|
3823
iShares US Telecommunications ETF
IYZ
$1.28B
| $2.07M | ﹤0.01% |
63,851
-270,697
| -81% | -$9.12M |
|
3824
Praxis Precision Medicines
PRAX
$9.63B
| $2.07M | ﹤0.01% |
7,465
+3,377
| +83% | +$916K |
|
3825
Coca-Cola Consolidated
COKE
$13.2B
| $2.07M | ﹤0.01% |
52,490
+15,510
| +42% | +$617K |
|
Similar funds
Israel Englander's Q3 2021 Portfolio in Review
As of Q3 2021, Israel Englander held 7,698 positions worth $167B, up 2.3% from $163B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Israel Englander's Q3 2021 filing shows 1,245 new, 2,719 increased, 2,446 reduced and 981 closed positions. Its largest new stake was Sight Sciences: 1,577,092 shares worth $35.8M. The largest sale was Alexion Pharmaceuticals, an estimated $887M.
By sector, the portfolio is most concentrated in Miscellaneous at 58% of assets, up from 55% a quarter earlier, followed by Technology and Financials.
- Israel Englander's largest Q3 2021 buy was Sight Sciences: 1,577,092 shares worth $35.8M.
- Israel Englander added most to State Street SPDR S&P 500 ETF Trust in Q3 2021, an estimated $643M increase.
- Israel Englander's biggest Q3 2021 reduction was Apple, cutting an estimated $694M.
- Israel Englander fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $887M.
- Israel Englander's ten largest holdings make up 18% of its $167B portfolio in Q3 2021.
- Israel Englander opened 1,245 new positions and closed 981 in Q3 2021.
- Israel Englander's portfolio value rose 2.3% quarter-over-quarter to $167B.
Based on Millennium Management's 13F filing for Q3 2021, filed 15 Nov 2021.